A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

SECTION 1. Section 329-14, Hawaii Revised Statutes, is 1 2 amended by amending subsections (f) and (g) to read as follows: Stimulants. Unless specifically excepted or unless 3 "(f) 4 listed in another schedule, any material, compound, mixture, or 5 preparation which contains any quantity of the following 6 substances having a stimulant effect on the central nervous 7 system, including its salts, isomers, and salts of isomers: 8 (1) Aminorex; 9 (2) Cathinone; 10 (3) Fenethylline; 11 (4) Methcathinone; 12 (5) N-ethylamphetamine; 13 (6) 4-methylaminorex; 14 N, N-dimethylamphetamine; and (7) 15 (8) Substituted cathinones, any compound, except bupropion or compounds listed under a different schedule, 16 **17** structurally derived from 2-aminopropan-1-one by 18 substitution at the 1-position with either phenyl,

1	napn	thyi, or thiophene ring systems, whether or not
2	the	compound is further modified in any of the
3	foll	owing ways:
4	(A)	By substitution in the ring system to any extent
5		with alkyl, alkylenedioxy, alkoxy, haloalkyl,
6		hydroxyl, or halide substituents, whether or not
7		further substituted in the ring system by one or
8		more other univalent substituents;
9	(B)	By substitution at the 3-position with an acyclic
10		alkyl substituent; or
11	(C)	By substitution at the 2-amino nitrogen atom with
12		alkyl, dialkyl, benzyl, or methoxybenzyl groups,
13		or by inclusion of the 2-amino nitrogen atom in a
14		cyclic structure.
15	Some	other trade names: Mephedrone (2-methylamino-1-
16	p-to:	lylpropan-1-one), also known as 4-
17	meth	ylmethcathinone (4-MMC), methylephedrone or MMCAT;
18	Methy	ylenedioxypyrovalerone (MDPV, MDPK); [and]
19	methy	ylone or 3,4-methylenedioxymethcathinone[-]; and
20	1-(be	enzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-
21	one,	monohydrochloride, also known as Ethylone, bk-

1		MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-
2		ethylcathinone; bk-Methylenedioxyethylamphetamine.
3	(g)	Any of the following cannabinoids, their salts,
4	isomers,	and salts of isomers, unless specifically excepted,
5	whenever	the existence of these salts, isomers, and salts of
6	isomers i	s possible within the specific chemical designation:
7	(1)	Tetrahydrocannabinols; meaning tetrahydrocannabinols
8		naturally contained in a plant of the genus Cannabis
9		(cannabis plant), as well as synthetic equivalents of
10		the substances contained in the plant, or in the
11		resinous extractives of Cannabis, sp. or synthetic
12		substances, derivatives, and their isomers with
13		similar chemical structure and pharmacological
14		activity to those substances contained in the plant,
15		such as the following: Delta 1 cis or trans
16		tetrahydrocannabinol, and their optical isomers; Delta
17		6 cis or trans tetrahydrocannabinol, and their optical
18		isomers; and Delta 3,4 cis or trans-
19		tetrahydrocannabinol, and its optical isomers (since
20		nomenclature of these substances is not
21		internationally standardized, compounds of these

1		structures, regardless of numerical designation of
2		atomic positions, are covered);
3	(2)	Naphthoylindoles; meaning any compound containing a
4		3-(1-naphthoyl) indole structure with substitution at
5		the nitrogen atom of the indole ring by a alkyl,
6		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
8		ethyl group, whether or not further substituted in the
9		indole ring to any extent and whether or not
10		substituted in the naphthyl ring to any extent;
11	(3)	Naphthylmethylindoles; meaning any compound containing
12		a 1H-indol-3-yl-(1-naphthyl) methane structure with
13		substitution at the nitrogen atom of the indole ring
14		by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
16		2-(4-morpholinyl) ethyl group whether or not further
17		substituted in the indole ring to any extent and
18		whether or not substituted in the naphthyl ring to any
19		extent;
20	(4)	Naphthoylpyrroles; meaning any compound containing a
21		3-(1-naphthoyl) pyrrole structure with substitution at

1		the nitrogen atom of the pyrrole ring by a alkyl,
2		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
4		ethyl group whether or not further substituted in the
5		pyrrole ring to any extent, whether or not substituted
6		in the naphthyl ring to any extent;
7	(5)	Naphthylmethylindenes; meaning any compound containing
8		a naphthylideneindene structure with substitution at
9		the 3-position of the indene ring by a alkyl,
10		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
12		ethyl group whether or not further substituted in the
13		indene ring to any extent, whether or not substituted
14		in the naphthyl ring to any extent;
15	(6)	Phenylacetylindoles; meaning any compound containing a
16		3-phenylacetylindole structure with substitution at
17		the nitrogen atom of the indole ring by a alkyl,
18		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
19		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)

ethyl group whether or not further substituted in the

20

1		indole ring to any extent, whether or not substituted
2		in the phenyl ring to any extent;
3	(7)	Cyclohexylphenols; meaning any compound containing a
4		2-(3-hydroxycyclohexyl) phenol structure with
5		substitution at the 5-position of the phenolic ring by
6		a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
7		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
8		2-(4-morpholinyl) ethyl group whether or not
9		substituted in the cyclohexyl ring to any extent;
10	(8)	Benzoylindoles; meaning any compound containing a
11		3-(benzoyl) indole structure with substitution at the
12		nitrogen atom of the indole ring by a alkyl,
13		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
15		ethyl group whether or not further substituted in the
16		indole ring to any extent and whether or not
17		substituted in the phenyl ring to any extent;
18	(9)	2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
19		pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
20		napthalenylmethanone (another trade name is WIN
21		55,212-2);

```
1
         (10)
               (6a, 10a) -9-(hydroxymethyl) -6, 6-dimethyl-3-(2-
2
              methyloctan-2-yl)-6a,7,10,10a-
3
               tetrahydrobenzo[c]chromen-1-ol (other trade names are:
 4
              HU-210 and HU-211);
5
        (11)
              Tetramethylcyclopropanoylindoles; meaning any compound
              containing a 3-tetramethylcyclopropanoylindole
6
7
              structure with substitution at the nitrogen atom of
8
              the indole ring by an alkyl, haloalkyl, cyanoalkyl,
9
              alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
10
              methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl,
11
              1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-
12
              morpholinyl) methyl, or tetrahydropyranylmethyl group,
13
              whether or not further substituted in the indole ring
14
              to any extent and whether or not substituted in the
15
              tetramethylcyclopropyl ring to any extent;
16
        (12)
              N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
17
              its optical, positional, and geometric isomers, salts,
18
              and salts of isomers (Other names: APINACA, AKB48);
19
        (13)
              Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
20
              optical, positional, and geometric isomers, salts, and
21
              salts of isomers (Other names: PB-22; OUPIC);
```

```
1
               Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
         (14)
2
               carboxylate, its optical, positional, and geometric
3
               isomers, salts, and salts of isomers (Other names: 5-
4
               fluoro-PB-22; 5F-PB-22);
5
        (15)
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-methyl-1-oxobutan-2-yl)
6
               fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
7
               positional, and geometric isomers, salts, and salts of
               isomers (Other names: AB-FUBINACA); [and]
8
9
        (16)
              N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
               indazole-3-carboxamide, its optical, positional, and
10
               geometric isomers, salts, and salts of isomers (Other
11
12
               names: ADB-PINACA) [-];
13
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
        (17)
14
               (cyclohexylmethyl) -1H-indazole-3-carboxamide, its
               optical, positional, and geometric isomers, salts, and
15
16
               salts of isomers (Other names: AB-CHMINACA);
17
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
        (18)
18
               indazole-3-carboxamide, and geometric isomers, salts,
19
               and salts of isomers (Other names: AB-PINACA);
```

```
1
        (19) [1-(5-fluoropentyl)-1H-indazol-3-yl] (naphthalen-1-
2
              yl) methanone, and geometric isomers, salts, and salts
3
              of isomers (Other names: THJ-2201);
4
        (20)
              Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
5
              valinate, and geometric isomers, salts, and salts of
6
              isomers (other names: FUB-AMB);
7
        (21)
              (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
8
              carboxamido) - 3 - methylbutanoate, and geometric isomers,
9
              salts, and salts of isomers (Other names: 5-fluoro-
10
              AMB, 5-fluoro-AMP);
11
              N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
        (22)
12
              indazole-3-carboxamide, and geometric isomers, salts,
13
              and salts of isomers (Other names: AKB48 N-(5-
14
              fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
15
              analog, 5F-APINACA);
16
              N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
        (23)
17
              geometric isomers, salts, and salts of isomers (Other
18
              names: STS-135, 5F-APICA; 5-fluoro-APICA); and
              Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
19
        (24)
20
              caboxylate, and geometric isomers, salts, and salts of
21
              isomers (Other names: NM2201)."
```

1	SECT	ION 2. Section 329-18, Hawaii Revised Statutes, is
. 2	amended b	y amending subsection (e) to read as follows:
3	"(e)	Narcotic drugs. Unless specifically excepted or
4	unless li	sted in another schedule, any material, compound,
5	mixture,	or preparation containing any of the following narcotic
6	drugs, or	their salts, or alkaloid, in limited quantities as set
7	forth bel	ow:
8	(1)	Not more than 1.8 grams of codeine, or any of its
9		salts, per 100 milliliters or not more than 90
10		milligrams per dosage unit, with an equal or greater
11		quantity of an isoquinoline alkaloid of opium;
12	(2)	Not more than 1.8 grams of codeine, or any of its
13		salts, per 100 milliliters or not more than 90
14		milligrams per dosage unit, with one or more active,
15		nonnarcotic ingredients in recognized therapeutic
16		amounts;
17	[-(3)	Not more than 300 milligrams of dihydrocodeinone
18		(Hydrocodone), or any of its salts, per 100
19		milliliters or not more than 15 milligrams per dosage
20		unit, with a fourfold or greater quantity of an
21		isoquinoline alkaloid of opium provided that these

1		narcotic drugs shall be monitored pursuant to section
2		329-101;
3	(4)	Not more than 300 milligrams of dihydrocodeinone
4		(Hydrocodone), or any of its salts per 100 milliliters
5		or not more than 15 milligrams per dosage unit, with
6		one or more active, nonnarcotic ingredients in
7		recognized therapeutic amounts provided that these
8		narcotic drugs shall be monitored pursuant to section
9		329-101;
10	(5)]	(3) Not more than 1.8 grams of dihydrocodeine, or any
11		of its salts, per 100 milliliters or not more than 90
12		milligrams per dosage unit, with one or more active,
13		nonnarcotic ingredients in recognized therapeutic
14		amounts;
15	[-(6)]	(4) Not more than 300 milligrams of ethylmorphine, or
16		any of its salts, per 100 milliliters or not more than
17		15 milligrams per dosage unit, with one or more
18		ingredients in recognized therapeutic amounts;
19	[(7)]	(5) Not more than 500 milligrams of opium per 100
20		milliliters or per 100 grams, or not more than 25
21		milligrams per dosage unit, with one or more active

```
1
               nonnarcotic ingredients in recognized therapeutic
2
               amounts;
         [\frac{(8)}{(8)}] (6) Not more than 50 milligrams of morphine or any of
3
4
               its salts, per 100 milliliters or per 100 grams with
5
               one or more active, nonnarcotic ingredients in
6
               recognized therapeutic amounts; and
7
         \left[\frac{(9)}{(9)}\right] (7) Buprenorphine."
8
         SECTION 3. Section 329-20, Hawaii Revised Statutes, is
9
    amended as follows:
10
          1. By amending subsection (b) to read:
11
                Depressants. Any material, compound, mixture, or
          "(b)
12
    preparation which contains any quantity of the following
13
    substances, including its salts, isomers, esters, ethers, and
14
    salts of isomers, whenever the existence of these isomers,
    esters, ethers, and salts is possible within the specific
15
16
    chemical designation, that has a degree of danger or probable
17
    danger associated with a depressant effect on the central
18
    nervous system:
19
          (1)
             Alprazolam;
20
         (2) Barbital;
21
         (3) Bromazepam;
```

```
1
         (4)
               Butorphanol;
2
         (5)
               Camazepam;
3
               Carisoprodol;
         (6)
4
         (7)
               Chloral betaine;
5
         (8)
               Chloral hydrate;
6
         (9)
               Chlordiazepoxide;
7
        (10)
               Clobazam;
8
        (11)
               Clonazepam;
9
        (12)
              Clorazepate;
10
        (13)
               Clotiazepam;
11
               Cloxazolam;
        (14)
12
        (15)
              Delorazepam;
13
        (16)
               Dichloralphenazone (Midrin);
14
        (17)
              Diazepam;
15
        (18)
               Estazolam;
16
        (19)
               Ethchlorvynol;
17
        (20)
               Ethinamate;
18
        (21)
               Ethyl loflazepate;
19
        (22)
               Fludiazepam;
20
        (23)
               Flunitrazepam;
21
```

Flurazepam;

(24)

```
1
                Fospropofol (Lusedra);
         (25)
 2
         (26)
               Halazepam;
 3
         (27)
               Haloxazolam;
 4
         (28)
                Ketazolam;
 5
         (29)
               Loprazolam;
 6
         (30)
               Lorazepam;
 7
         (31)
               Lormetazepam;
8
         (32)
               Mebutamate;
9
         (33)
               Medazepam;
10
         (34)
               Meprobamate;
11
         (35)
               Methohexital;
12
         (36)
               Methylphenobarbital (mephorbarbital);
13
         (37)
               Midazolam;
14
         (38)
               Nimetazepam;
15
         (39)
               Nitrazepam;
16
         (40)
               Nordiazepam;
17
         (41)
               Oxazepam;
18
         (42)
               Oxazolam;
19
         (43)
               Paraldehyde;
20
               Petrichloral;
         (44)
21
         (45)
               Phenobarbital;
```

S.B. NO. 5.D. 2

```
1
        (46)
               Pinazepam;
2
        (47)
             Prazepam;
3
        (48)
              Quazepam;
4
        (49) Suvorexant;
5
       [(49)] (50) Temazepam;
6
       [(50)] (51) Tetrazepam;
7
       [<del>(51)</del>] (52) Triazolam;
8
       \left[\frac{52}{52}\right] (53) Zaleplon;
       [(53)] (54) Zolpidem; and
9
       [<del>(54)</del>] (55) Zopiclone (Lunesta)."
10
11
         2. By amending subsection (g) to read:
12
          " (q)
                Narcotic drugs. Unless specifically excepted or
    unless listed in another schedule, any material, compound,
13
    mixture, or preparation containing any of the following narcotic
14
15
    drugs, or their salts calculated as the free anhydrous base or
16
    alkaloid, in limited quantities as set forth below:
               Not more than one milligram of difenoxin and not less
17
          (1)
               than twenty-five micrograms of atropine sulfate per
18
               dosage unit; [and]
19
20
          (2)
               Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-
21
               diphenyl-3-methyl-2-propionoxybutane) [-]; and
```

1	(3) 2-[(dimethylamino)methyl]-1-(3-
2	methoxyphenyl)cyclohexanol, its salts, optical and
3	geometric isomers and salts of these isomers
4	(including tramadol)."
5	SECTION 4. Statutory material to be repealed is bracketed
6	and stricken. New statutory material is underscored.
7	SECUTION E This Not shall take offest on January 7, 2050

Report Title:

Uniform Controlled Substances Act

Description:

Updates chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in federal law on controlled substances; amends section 329-20, HRS, to add new controlled substances federally scheduled as required under section 329-11, HRS; adds a new synthetic cathinone and eight new synthetic cannabinoids to section 329-14, HRS. Effective 1/7/2059. (SD2)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.